Report date: 2026-09-13 | Price data: 2026-09-11 close (Friday); all price/market data in the notes are as of that time, cross-checked across multiple sources including East Money, Securities Times (stcn), Cailian Press (cls), Sina Finance, Jiufang Zhitou, and Baidu Stock Market | Sources: 30 | Report engine: v1 (v2 available)

Report engine upgraded to v2 (2026-09-24)

This report was generated by engine v1. v2: Rebuilt like a professional research note: a conclusion-first summary with where the evidence differs from market expectations, a dated catalyst calendar, a watch list you can track, and a one-week price range based on historical volatility, all in a tighter write-up. What's new

View PDF Download Word Download Markdown

Price history

Loading price history...

Latest market data

Close	34.07 (+3.24% on the day; +1.01% over 5 sessions; -2.57% over 20 sessions)
Market cap	CNY 15.14 billion
P/E (TTM)	24.63x (1th percentile over 5.2 years)
P/B (MRQ)	3.66x (3th percentile over 5.2 years)
P/S (TTM)	5.09x (1th percentile over 5.2 years)
52-week range	32.07 (2026-09-16) – 52.22 (2026-02-25)
Moving averages	MA5 33.53 / MA10 33.32 / MA20 33.74 / MA60 35.04
MACD (12,26,9)	DIF -0.458, DEA -0.572, histogram 0.227
RSI	RSI6 61.5 / RSI14 50.3
Bollinger bands (20,2)	Upper 35.78 / middle 33.74 / lower 31.7
Volume	1.39x the 20-day average
One-week range (about 68% coverage)	32.65 – 35.12 (-4.2% ~ +3.1%)
One-week range (about 95% coverage)	31.48 – 36.72 (-7.6% ~ +7.8%)

As of the 2026-09-30 close; calculated from daily price data (adjusted prices) and refreshed automatically each trading day. The one-week range reflects historical volatility only and is not a forecast. The report below was written on 2026-09-13; its prices and short-term scenarios reflect data at that time.

Topchoice Medical Co., Inc. (600763)

Equity Research Report | Sector: Healthcare Services (Dental Care) | Report Date: September 13, 2026 | 2026-09-11 Close (Friday); all price/market data in this report are as of that point in time, cross-referenced from multiple sources including East Money, Securities Times stcn, Cailian Press cls, Sina Finance, 9fzt, and Baidu Finance

This report is automatically compiled and generated by AI based on public information, for reference only and does not constitute investment advice.

1. Core Summary

The core facts about Topchoice Medical are: 2026H1 revenue was RMB 1.586 billion, up 4.10% year-over-year; net profit attributable to parent was RMB 458 million, up 32.70% year-over-year, but non-GAAP net profit attributable to parent (excluding non-recurring items) was only RMB 325 million, up 5.74% year-over-year. The gap between the attributable and non-GAAP growth rates is nearly 27 percentage points, indicating that the headline high profit growth was affected by non-recurring gains and losses and the accounting restatement from the optometry asset acquisition, while the core operating growth remains at single-digit levels. In 2025, the company's revenue was RMB 2.913 billion and net profit attributable to parent was RMB 502 million, with overall performance growth having been relatively stagnant over the past three years.

The company remains overwhelmingly focused on dental care, with 2026H1 dental care revenue of RMB 1.412 billion, accounting for 89.05%, and revenue from within Zhejiang Province accounting for 90.50%. It relies on the "flagship hospital + branch hospitals + Dandelion partner" model, regional brand, doctor resources, and a low sales expense ratio to form competitive advantages. In 2026H1, gross margin rose to 42.95%, up 1.11 percentage points from the same period last year; 2025 net operating cash flow was RMB 811 million, up 6.2% year-over-year, demonstrating the still-evident cash flow characteristics of healthcare services where payment is collected before services are rendered.

The company's growth logic is shifting from high-margin implant expansion to post-volume-based procurement "volume offsetting price," release of doctor productivity, business structure optimization, and supply chain direct procurement cost reduction. In 2025, implant revenue declined 2.08%, while orthodontics revenue grew 7.63%; in 2026H1, general dentistry and orthodontics grew 8.30% and 5.32% respectively, but pediatric dentistry declined 0.59%, and out-of-province revenue declined 10% year-over-year. Regional concentration and cross-regional expansion capability remain important observation points. The company also completed a RMB 600 million related-party acquisition of optometry assets, with 2026H1 optometry revenue of RMB 74.47 million, accounting for 4.70%, providing a new source of business increment.

As of September 11, 2026, the company's stock price was RMB 32.75, close to the 52-week low of RMB 32.53, with a TTM P/E of approximately 23x and a static P/E of approximately 29x; the dynamic P/E of 15.88x is low because it annualizes the non-recurring gains and losses from the semi-annual report, and should not be directly used as a basis for normal valuation. On the technical front, RMB 32.5–32.6 is the near-term support zone, and RMB 33.4–33.5 is the near-term resistance zone. The current turnover rate is 1.52% and volume ratio is 0.94, indicating relatively light trading.

2. Company Overview

2.1 Basic Information

Item	Content
Stock Code	600763.SH
Company Full Name	Topchoice Medical Co., Inc.
Sector	Healthcare Services
Registered Location	Zhejiang Province
Headquarters	Hangzhou, Zhejiang
Listing Date	1996-10-30
Historical Background	Stock code 600763 originally corresponded to "Beijing Zhongyan Tango Down Products Co., Ltd. / Zhongyan Textile" (down products, textile business), was already ST around 2001, and its main business was once suspended; later, the Topchoice group injected medical assets through a reverse merger around 2006, transforming it into a dental healthcare service company. Financial data from 1996–2005 cannot be regarded as dental healthcare data.
Number of Employees	Approximately 6,224 (as of end-2025, source: Simply Wall St, non-official source)
Total Shares	Approximately 447 million shares (approximately 447.29 million shares), free float essentially identical to total shares (fully circulating)
Total Market Cap	Approximately RMB 14.5–16.8 billion range (Stockstar lists RMB 14.556 billion; Simply Wall St previously listed CN¥15.7–16.8b), fluctuates with market conditions, for reference only
Website	www.tcmedical.com.cn

2.2 Main Business and Product Layout

Healthcare Services (Dental Care, 2026H1 revenue RMB 1.412 billion, 89.05%, gross margin 43.33%; 2025 revenue RMB 2.764 billion, 94.89%, gross margin 39.34%)
Optometry (newly consolidated in 2026H1, revenue RMB 74.47 million, 4.70%, gross margin 59.09%; in 2026H1 completed acquisition of 100% equity in 4 companies including Hangzhou Cunji Glasses, total transaction amount RMB 600 million)
Product Sales (2026H1 revenue RMB 65.21 million, 4.11%, gross margin 21.87%; 2025 revenue RMB 86.09 million, 2.96%, gross margin 19.22%)
Construction Engineering (2026H1 revenue RMB 29.07 million, 1.83%, gross margin 26.41%)
Others (2026H1 revenue RMB 4.92 million, 0.31%)

2.3 Industry Chain Position and Cost-Profit Structure

Topchoice Medical is a leading domestic dental healthcare service provider ("Dental Moutai"), expanding through the "regional flagship hospital + branch hospitals" and "Dandelion Plan (core doctors holding equity in branch hospitals)" model, with business highly concentrated in Zhejiang Province (2026H1 revenue from within Zhejiang Province accounted for 90.50%). The company explicitly states it "does not manufacture dental implants or other medical devices and consumables"; upstream it connects with dental medical equipment and consumable suppliers, essentially being a purchaser of consumables/equipment; downstream it mainly faces patients and related public welfare projects. Its industry chain positioning is in the middle-to-service/channel end of the smile curve.

The company explicitly states it "does not manufacture dental implants or other medical devices and consumables"; upstream it connects with dental medical equipment and consumable suppliers, essentially being a purchaser of consumables/equipment. Source: Company announcement (Sina Finance)
Procurement Category One: Dental implants (core consumable for implant business, accounting for approximately 20% of the company's healthcare service revenue in terms of magnitude) — high-end includes Straumann, Danaher/Dentsply Sirona and other European and American brands; mid-range includes Korean brands Osstem and Dentium; domestic brands include Weigao Jieliya, Changzhou Baikangte, Jiangsu Chuangying, etc. After volume-based procurement, the average price of imported dental implants was significantly compressed (public procurement high-end brands originally RMB 4,000–6,000/set, others RMB 2,000–3,500/set; after volume-based procurement, the average winning bid dropped to just over RMB 900, a decrease of approximately 55%).
Procurement Category Two: Orthodontic materials — traditional brackets and clear aligners (clear aligners dominated by Align Technology (Invisalign) of the US and Angelalign of China).
Procurement Category Three: Equipment — dental chairs, CBCT, intraoral scanners, microscopes, sterilization equipment, etc., long dominated by foreign companies such as KaVo, Sirona, and Yiyou; domestic substitution (Meiya Optoelectronics, Langshi Instruments CBCT) is accelerating.
Procurement Model Evolution (Key Change): The company's 2025 annual report disclosed that in 2025 it upgraded its procurement model from "relying on supplier networks" to "self-operated model, directly procuring core consumables such as dental implants from manufacturers" to reduce procurement costs; and emphasized "group centralized procurement + intelligent inventory management." This indicates the company previously had some dependence on upstream distribution channels and is now seeking direct procurement from manufacturers, reflecting a certain scale-based bargaining power over upstream, but core dental implants remain constrained by foreign/Korean brand supply, representing an intermediate state of "large-scale purchaser, still brand-dependent for individual products," not a complete price taker, nor can it be said to have pricing power over upstream.
Supplier Concentration: Specific top-five supplier percentages were not disclosed in the retrieved materials; this gap needs to be filled based on the latest annual report.
Customers are highly dispersed individual patients and a small number of public welfare projects (the company states "downstream mainly faces patients and related public welfare projects"). Source: Company announcement (Sina Finance)
Most visits are self-paid (implants and orthodontics are consumer-type services not covered by medical insurance), so there is no typical "major customer concentration" issue, nor are there automotive-parts-style OEM "annual price reduction" clauses.
Contradictory data requiring special annotation: A line on the Tonghuashun F10 "Business Analysis" page shows "Top 5 customers: total sales of RMB 30.6578 million, accounting for 91.46% of operating revenue," but the "customers" listed thereafter are the company's own subsidiary hospitals including Hangzhou Dental Hospital Co., Ltd., Hangzhou Chengxi Dental Hospital Co., Ltd., and Ningbo Dental Hospital. RMB 30.6578 million also clearly does not match revenue at the RMB 1.4 billion level. It is judged that this entry is mislabeled under a segment/inter-company related-party transaction basis and should not be used as external customer concentration; for external patients, customer concentration is essentially close to zero. This point comes from a single source and is internally contradictory, and is explicitly flagged as questionable.
Structural Bargaining Dynamics: The value core of the dental healthcare industry lies in doctors and treatment services ("technical service fees"), and consumables/implants actually account for a relatively low proportion of terminal charges (industry data estimates that dental implants and consumables together account for approximately 10%–20% of charges). Therefore, downstream "price pressure" on the company mainly comes from medical insurance cost control/volume-based procurement policies regulating the charging end, rather than customer bargaining.
No reliable, cross-verifiable specific data on accounts receivable/turnover days/contract liabilities was retrieved (this search focused on qualitative materials and did not pull annual report balance sheet line items). It should be noted that the natural characteristic of healthcare services is "collect payment before service" (prepayments/contract liabilities, good cash flow). The company states "operating cash flow continues to grow," with 2026H1 net operating cash flow of RMB 400 million (+7.36%) and 2025H1 of RMB 355 million (+9.7%), and book accounts receivable have historically been relatively small — but the above specific working capital indicators were not obtained from verifiable sources in this search. It is recommended to refer to the latest annual report's "accounts receivable turnover days/contract liabilities/accounts payable" line items and not to directly cite estimated values.
Supplier Concentration: Specific top-five supplier percentages were not disclosed in the retrieved materials; this gap needs to be filled based on the latest annual report. Customer Concentration: The company states downstream mainly faces patients and related public welfare projects, with customers highly dispersed, and concentration for external patients is essentially close to zero; the Tonghuashun F10 entry "top 5 customers accounting for 91.46% of operating revenue" lists entities that are the company's subsidiary hospitals, mislabeled under an inter-company related-party transaction basis, explicitly questionable and should not be used as external customer concentration.

Gross Margin

Year	Gross Margin	Net Margin	Brief Explanation
2020	45.16	—	Pre-volume-based procurement high-margin era, high per-case prices for implants/orthodontics, high doctor service premium
2021	46.05	28.27	Gross margin peak; implant/orthodontics share increased, consumption upgrade
2022	40.81	—	From 2022, special governance of dental implants + weakening consumer confidence, expected dual decline in implant "technical service fees" and material costs pressured gross margin
2023	38.53	—	In 2023, implant system volume-based procurement landed, consumable prices declined, gross margin stepped down again
2024	38.50	—	Volume-based procurement "volume offsetting price" continued, gross margin basically bottomed
2025	38.63	20.19	Gross margin stabilized with slight increase; but net margin fell significantly from 28.27% in 2021, implant revenue that year −2.08%

Topchoice Medical is an institution in the middle-to-"service/channel end" of the smile curve — it does not control upstream R&D and manufacturing of implants/consumables/equipment (upstream constrained by foreign and Korean brand and volume-based procurement supply landscape), nor does it rely on advertising traffic for customer acquisition (extremely low sales expense ratio, only about 0.9% in 2024, in sharp contrast to Yaboshi's high-marketing model at 27%), but rather relies on regional brand + flagship hospital expert resources + doctor partnership mechanism to occupy a high-margin position in Zhejiang dental services. The drivers for further gross margin improvement are not raw material price increases/decreases, but rather: ① Release of doctor productivity (major department system reform, doctor partners) + economies of scale diluting fixed costs; ② Upward business structure shift (volume growth in essential services such as general dentistry/restoration, increasing share of own-brand consumables); ③ Post-volume-based procurement implant "volume offsetting price" + full price band penetration (the company proposes to increase Zhejiang implant market share from approximately 5% to 30% within three years). The risk side is long-term unsuccessful out-of-province expansion (out-of-province revenue 2026H1 year-over-year −10%).

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

Reporting Period	Operating Revenue	YoY	Net Profit Attributable to Parent	YoY
2026H1 (reporting period 2026-06-30, announcement date 2026-08-15)	RMB 1.586 billion (RMB 1,586,118,351.78)	+4.10%	Net profit attributable to parent RMB 458 million (approximately RMB 458,411,200); non-GAAP net profit attributable to parent RMB 325 million; net profit (including minority interests, income statement basis) RMB 521 million	Net profit attributable to parent YoY +32.70%; non-GAAP net profit attributable to parent YoY +5.74%; non-GAAP EPS RMB 0.73
2026Q2 (single quarter)	RMB 831 million	+6.65%	Net profit attributable to parent RMB 272 million; non-GAAP attributable to parent RMB 141 million	Net profit attributable to parent +68.02%; non-GAAP attributable to parent +4.19%
2026Q1 (reporting period 2026-03-31, announcement date 2026-04-18)	RMB 755 million	+1.43%	Net profit attributable to parent RMB 187 million; non-GAAP RMB 185 million	Net profit attributable to parent +1.66%; non-GAAP +1.37%
2025 Annual Report (reporting period 2025-12-31, announcement date 2026-04-18)	RMB 2.913 billion	+1.37%	Net profit attributable to parent RMB 502 million; non-GAAP attributable to parent RMB 496 million	Net profit attributable to parent +0.19%; non-GAAP attributable to parent -0.04%
2025Q4 (single quarter)	RMB 623 million	-2.77%	Net profit attributable to parent -RMB 12 million (loss)	Data missing
2024 (historical revenue/net profit attributable to parent)	RMB 2.874 billion (RMB 2,874 million)	Data missing	Net profit attributable to parent RMB 501 million (RMB 501.00 million)	Data missing
2023 (historical revenue/net profit attributable to parent)	RMB 2.847 billion (RMB 2,847 million)	Data missing	Net profit attributable to parent RMB 500 million (RMB 500.44 million)	Data missing
2022 (historical revenue/net profit attributable to parent)	RMB 2.719 billion (RMB 2,719 million)	Data missing	Net profit attributable to parent RMB 548 million (RMB 548.27 million)	Data missing
2021 (historical revenue/net profit attributable to parent)	RMB 2.781 billion (RMB 2,781 million)	Data missing	Net profit attributable to parent RMB 703 million (RMB 702.81 million)	Data missing

Data sources: East Money Data Center, Stockstar, stockanalysis.com; 2026H1 segment businesses: general dentistry RMB 427 million (+8.30%), orthodontics RMB 241 million (+5.32%), implants/restoration/pediatrics YoY +4.16%/+5.91%/-0.59%; 2025 by business: implants RMB 519 million (-2.08%), orthodontics RMB 510 million (+7.63%), pediatrics RMB 487 million (-2.69%), restoration RMB 466 million (+0.72%), general dentistry RMB 783 million (+2.27%). 2025 gross margin approximately 39%, net margin 20.19%, total of three expenses 13.56% (down YoY), net operating cash flow RMB 811 million (YoY +6.2%), full-year outpatient visits 3.5736 million (YoY +1.14%). 2026H1 gross margin 42.95% (YoY +1.11pct), expense ratio 13.12% (YoY -0.37pct).

Key Warning (Important Uncertainty): The huge difference between 2026H1 net profit attributable to parent +32.70% and non-GAAP only +5.74% stems from the accounting restatement (retrospective adjustment) caused by the completion in April 2026 of the same-control acquisition (100% equity in four companies: Hangzhou Cunji Glasses, Ningbo Guangji Optometry, Hangzhou Guangji Optometry, Xinchang Guangji Glasses), generating substantial non-recurring gains and losses. Therefore, the headline "net profit +32.7%" is misleading, and the true operating growth should be measured by non-GAAP (+5.74%); the year-over-year base (2025H1) was also restated, and the comparability of the YoY growth rate requires caution. Source: CICC research report dated 2026-08-17. Historically, 2021-2025 revenue/net profit attributable to parent reflect essentially stagnant performance over the past three years, with prior declines. Some data comes from third-party aggregation sites and domestic portals, and there are minor differences in amounts/basis (attributable to parent vs. including minority interests); formal citations should be based on the company's SSE announcements.

3.2 Earnings Forecast

Source: East Money F10 consensus estimates (emweb.securities.eastmoney.com/ProfitForecast/Index?code=SH600763), latest update covering 14-15 institutions. Another earlier snapshot (only 12 institutions): 2026E net profit RMB 594.3 million, EPS 1.3283; 2027E RMB 679.1 million, 1.5198; 2028E RMB 772.5 million, 1.7272. Major individual forecasts (net profit attributable to parent, RMB 100 million): CICC (2026-08-17) 2026E 5.80/2027E 6.38; Huatai Securities (2026-08-14/16) 5.95/6.85/7.72; Huachuang Securities (2026-05-07) 6.23/7.05/8.11; CITIC Construction Investment (2026-05-18) 6.08/7.01/8.04; Industrial Securities (2026-05-15) 5.93/6.58/7.18; CITIC Securities (2026-04-30) 5.85/6.71/7.55; Guotai Haitong (2026-05-05) EPS 1.30/1.46/1.66; Sinolink Securities (2026-04-22) 5.99/7.06/8.18, EPS 1.34/1.58/1.83; Kaiyuan Securities (2026-04-21 and 2026-08-18 update) 6.24/7.33/8.83; Southwest Securities (2026-04-21) 5.87/6.73/7.66; Guolian Minsheng (2026-04-21) 6.01/6.96/7.69; Soochow Securities (2026-04-20) 5.51/6.18/6.78; Zhongtai Securities (2026-04-23) 5.85/6.65/7.24; Shenwan Hongyuan (2026-08-31) EPS 1.34/1.52/1.68; China Galaxy (2026-08-27) EPS 1.43/1.45/1.62; Northeast Securities (2026-08-21) EPS 1.46/1.53/1.67. Divergence is significant (Soochow lowest at RMB 551 million vs. Kaiyuan highest at RMB 624 million), reflecting differing judgments on volume-based procurement/orthodontics policy and new hospital/optometry increments; many institution forecasts are old data from April 2026 annual report commentary, and only a few including CICC, Huatai, Kaiyuan, Shenwan, Galaxy, and Northeast updated after the August semi-annual report.

Year	Operating Revenue	Net Profit Attributable to Parent	Net Profit Growth Rate	Earnings Per Share (EPS)
2026E (East Money F10 consensus estimates, covering 14-15 institutions)	RMB 3.363 billion	RMB 601.3 million	YoY +15%~+25% (aggregated basis, 2026 net profit forecast range approximately RMB 551 million–624 million, average approximately RMB 590–600 million)	RMB 1.3453 (net assets per share RMB 10.79, ROE 12.68%)
2027E (East Money F10 consensus estimates, covering 14-15 institutions)	RMB 3.783 billion	RMB 677.3 million	Data missing (forecast range approximately RMB 620–730 million)	RMB 1.5158 (net assets per share RMB 12.16, ROE 12.73%)
2028E (East Money F10 consensus estimates, covering 14-15 institutions)	RMB 4.225 billion	RMB 765.7 million	Data missing (forecast range approximately RMB 680–880 million)	RMB 1.7121 (net assets per share RMB 13.67, ROE 12.79%)
2025A (actual, for comparison)	RMB 2.913 billion	RMB 502 million (attributable to parent)	+0.19%	RMB 1.1293

3.3 Valuation Level and Institutional Ratings

Institution	Rating	Date	Remarks
Tonghuashun iNews summary (8 institutions over past 6 months)	3 Buy/2 Overweight/2 Recommend/1 Outperform	2026-04-23 summary	2026 target price high RMB 55.88, low RMB 53.20, average RMB 54.54
Baidu Finance (stock overview page)	Data missing (ratings not matched individually)	Updated approximately 2026-08-17	Target average price RMB 57.74, target high RMB 67.00, target low RMB 48.48; named research reports: CICC 2026-08-17 Buy 53.20, Huatai 2026-08-16 Buy 55.88, Huachuang 2026-05-08 Buy 63.00, Guotai Haitong 2026-05-05 Buy 49.41. Report notes its target average price is inconsistent with the listed individual stocks, and the high/low cannot be matched one-to-one; questionable, not adopted as authoritative value
Jingguan Zhixun	Data missing	2026-05-22	Composite target price at that time RMB 53.00
CICC	Outperform (Buy)	2026-08-17	Target price RMB 53.20; 2026E net profit RMB 580 million/2027E RMB 638 million
Huatai Securities	Buy	2026-08-14/16	Target price RMB 55.88; 2026E 5.95/2027E 6.85/2028E 7.72 RMB 100 million
Huachuang Securities	Buy	2026-05-07 (Baidu lists 2026-05-08)	Target price RMB 63.00; 2026E 6.23/2027E 7.05/2028E 8.11 RMB 100 million
CITIC Construction Investment	Data missing (rating not stated)	2026-05-18	No target price; 2026E 6.08/2027E 7.01/2028E 8.04 RMB 100 million
Industrial Securities	Data missing (rating not stated)	2026-05-15	No target price; 2026E 5.93/2027E 6.58/2028E 7.18 RMB 100 million
CITIC Securities	Data missing (rating not stated)	2026-04-30	Target price RMB 49.00; 2026E 5.85/2027E 6.71/2028E 7.55 RMB 100 million
Guotai Haitong	Overweight (Baidu lists Buy)	2026-05-05	Target price RMB 49.41; EPS 1.30/1.46/1.66
Sinolink Securities	Overweight	2026-04-22	2026E 5.99/2027E 7.06/2028E 8.18 RMB 100 million; EPS 1.34/1.58/1.83
Kaiyuan Securities	Buy	2026-04-21 and 2026-08-18 update	2026E 6.24/2027E 7.33/2028E 8.83 RMB 100 million
Southwest Securities	Data missing (rating not stated)	2026-04-21	2026E 5.87/2027E 6.73/2028E 7.66 RMB 100 million
Guolian Minsheng	Data missing (rating not stated)	2026-04-21	2026E 6.01/2027E 6.96/2028E 7.69 RMB 100 million
Soochow Securities	Buy	2026-04-20	No target price given; 2026E 5.51/2027E 6.18/2028E 6.78 RMB 100 million
Zhongtai Securities	Overweight	2026-04-23	2026E 5.85/2027E 6.65/2028E 7.24 RMB 100 million
Shenwan Hongyuan	Overweight	2026-08-31	EPS 1.34/1.52/1.68
China Galaxy	Buy	2026-08-27	EPS 1.43/1.45/1.62
Northeast Securities	Overweight	2026-08-21	EPS 1.46/1.53/1.67
Goldman Sachs	Sell	2026-08-24 related report	12-month target price RMB 38.30 (DCF-based), significantly lower than domestic brokerages, highlighting extreme divergence

Current valuation level (as of 2026-09-11 close): closing price RMB 32.75, day change -RMB 0.75 (-2.24%); total market cap/free float market cap RMB 14.556 billion; total shares/free float shares 444 million (fully circulating). Dynamic P/E 15.88x (Note: this basis uses 2026H1 performance annualized, and is low due to one-time gains/losses in H1, distorted); P/E (TTM) approximately 22.77–23.67x (different source bases: cls.cn reports 22.77, Sina/Baidu report 23.67, recommend using TTM approximately 23x as the standard and noting source date); static P/E approximately 29.0x (based on FY2025 net profit attributable to parent RMB 502 million); P/B 3.54–3.61x (Sina/cls 3.54; stcn/Baidu 3.61; AAStocks 3.64, updated 2026-09-02). Historical percentile: Jingguan Zhixun (2026-05-22) noted valuation was at historical lows at that time, with PE-TTM of 32.52 at the 0.66th percentile of the stock over the past 5 years (Note: this value is higher than the current price-implied PE, being data from an earlier date). Based on 2026E consensus EPS of RMB 1.3453, the current price of RMB 32.75 corresponds to 2026E PE of approximately 24.3x; based on 2027E 1.5158, approximately 21.6x; based on 2028E 1.7121, approximately 19.1x (self-calculated, not officially disclosed). Target price divergence is extreme: domestic brokerage average RMB 53–58, Goldman Sachs "Sell" target price only RMB 38.30. Valuation multiple bases are chaotic: dynamic PE 15.88 vs. TTM PE 22.77–23.67 vs. static PE 29.0 differ greatly, due to the annualization distortion from one-time gains in 2026H1. All price/valuation data as of 2026-09-11 close (or earlier, individually noted); financial data as of the 2026 semi-annual report (announced 2026-08-15).

4. Recent News and Announcements

4.1 Topchoice Medical (600763.SH) Company Identity Confirmation

Stock code 600763 corresponds to Topchoice Medical Co., Inc., listed on the Shanghai Stock Exchange Main Board, industry classification "Health and Social Work," previously named "ST Zhongyan." Main business is dental healthcare services, with 2025 healthcare service revenue accounting for approximately 92%–95%, and recent entry into the optometry business. Total shares 447,289,117 (before repurchase cancellation, per September 2026 disclosure). Legal representative/Chairman Wang Yi, actual controller Lü Jianming (holding through Hangzhou Baoqun Industrial Group). Sources: Shanghai Securities News annual report summary, etnet company information, East Money F10. Some sources show dates in 2026, latest announcement 2026-09.

4.2 Recent Announcement Timeline (June–September 2026)

Compiled from Stockstar company announcement page: 2026-06-03 10th Board of Directors 14th meeting resolution, centralized bidding repurchase plan announcement, amendment of compensation management system; 2026-06-10 directors, executives, other management personnel shareholding increase plan completion announcement; 2026-06-18 controlling shareholder partial share pledge announcement; 2026-06-26 2025 annual shareholders' meeting resolution; 2026-06-27 repurchase shares to reduce registered capital notice to creditors, repurchase report, acquisition of equity and related-party transaction progress announcement; 2026-06-30 first repurchase of company shares announcement; 2026-07-24 / 2026-07-31 announcements (not expanded); 2026-08-04 repurchase progress announcement; 2026-08-12 controlling shareholder partial share pledge and release announcement; 2026-08-14/15 2026 semi-annual report and summary; 2026-08-24 announcement of 2026 semi-annual results briefing; 2026-08-31 2026 semi-annual results briefing convening announcement; 2026-09-02 share repurchase implementation result and share change announcement; 2026-09-10 controlling shareholder partial share pledge and release announcement (Lin 2026-038).

4.3 Share Repurchase — Completed and Cancelled

Plan: Approved by board on 2026-06-03, shareholders' meeting on 2026-06-26; first disclosure date 2026/6/5; implementation period 2026/6/26–2027/6/25. Details: centralized bidding repurchase, price cap RMB 60.12/share, total funds no less than RMB 50 million and no more than RMB 100 million, all for cancellation to reduce registered capital. Implementation results (as of 2026-09-02 announcement, No. 2026-037): actual repurchase of 2,833,164 shares, 0.6334% of total shares; transaction price range RMB 33.53–36.66/share; total transaction amount RMB 99,497,383.85 (approximately RMB 99.50 million, close to the upper limit). Cancellation arrangement: The company cancelled the above 2,833,164 shares on September 2, 2026; after cancellation total shares decreased, and the shareholding ratio of controlling shareholder Baoqun Industrial and concert parties (including Lü Jianming) passively increased. Sources: Shanghai Securities News, Sina Finance, cnstock.com. Note: The repurchase price range of RMB 33.53–36.66 is the company's own purchase price, used to roughly infer the stock price range at that time; it may differ from the current latest stock price and needs separate verification.

4.4 Directors and Senior Management Shareholding Increase — Completed

Shareholding increase plan disclosed in February 2026 (Lin 2026-002), completed 2026-06-10. Participants: Chairman Wang Yi, Director Huang Yuhua, Board Secretary Zhang Hua, CFO Xu Guoxi, other management personnel Zhao Min. Planned total amount RMB 6–12 million; actual total increase of 188,700 shares, 0.042% of total shares, total amount RMB 7,757,842. Details: Wang Yi 49,600 shares/RMB 2,000,477; Huang Yuhua 63,000 shares/RMB 2,494,796; Zhang Hua 34,700 shares/RMB 1,508,467; Xu Guoxi 12,000 shares/RMB 500,985; Zhao Min 29,400 shares/RMB 1,253,117. Amount within the planned range, skewed toward the lower end. Sources: Cfi.cn, Shanghai Securities News, Gelonghui, Securities Daily.

4.5 Related-Party Acquisition of Optometry Assets (RMB 600 Million, High Premium Controversy, Regulatory Attention)

Disclosed on the evening of 2026-03-24 (Lin 2026-004): Acquisition of 100% equity in Hangzhou Cunji Glasses, Ningbo Guangji Optometry, Hangzhou Guangji Optometry, Xinchang Guangji Glasses, total transaction amount RMB 600 million, own funds. Targets are under Zhejiang Topchoice Eye Hospital Investment Management Co., Ltd., controlled by actual controller Lü Jianming, constituting a related-party transaction. Valuation: Valuation base date 2025-12-31, total appraised value of targets RMB 703 million, negotiated price RMB 600 million. Core target Hangzhou Cunji book net assets RMB 50.8779 million → appraised value RMB 703.2023 million, appreciation rate 1,282.14% (approximately 12x); 2025 revenue RMB 153 million, net profit RMB 55.5848 million; Ningbo Guangji 2025 revenue RMB 455,200, net profit -RMB 72,000; Xinchang Guangji revenue RMB 1.0118 million, net profit -RMB 77,500; Hangzhou Guangji had not actually commenced operations. Performance commitments: Hangzhou Cunji cumulative profit for 2026–2028 no less than RMB 180 million, cumulative for 2026–2030 no less than RMB 300 million, compensation cap RMB 600 million. Regulatory: SSE issued a regulatory work letter on 2026-03-24 (involving the listed company, directors and senior management, controlling shareholder and actual controller, intermediaries), focusing on transaction necessity and valuation fairness; the company replied within approximately one week (Economic Information Daily, 2026-04-10 report). Progress: 2026-04-09 extraordinary shareholders' meeting approved; 2026-06-27 progress announcement (Lin 2026-026) — the four targets completed industrial and commercial changes, payment made; and a supplementary agreement was signed, under which if Zhejiang Guangji Eye Hospital's "Cooperation Agreement" is terminated early, etc., the company has the right to require the transferor to repurchase at "original acquisition price of RMB 600 million + annualized LPR interest - performance compensation received - distributed profits." Controversy points (third-party reports): The counterparty was recently involved in two enforcement cases totaling RMB 520 million (Economic Information Daily, 2026-04-10). This item appears only in media reports such as Economic Information Daily, is under a media investigation basis, and has not been confirmed by company announcements; cite with caution. Strategic positioning: After the acquisition, promote "Bright Eyes and White Teeth," dental and optometry synergy; Hangzhou Cunji's core products include orthokeratology lenses (OK lenses, 2025 revenue share 26.20%), defocus lenses (share 32.07%). Sources: China Economic Net, Economic Information Daily, Shanghai Securities News, East Money announcement database.

4.6 Controlling Shareholder Share Pledge/Release (High Frequency in Recent Months, High Pledge Ratio)

2026-09-10 announcement (Lin 2026-038): Baoqun Industrial holds 151,589,199 shares (34.11% of total shares); this pledge of 2.95 million shares (1.95% of its holdings, 0.66% of total shares), released on the same day; pledgee Bank of Wenzhou Hangzhou Branch, pledge start date 2026.9.3, maturity date 2028.9.2, pledge financing purpose "off-system medical project needs"; release date 2026.9.9. After the transaction, Baoqun Industrial's cumulative pledged shares total 101,086,672, representing 66.68% of its holdings and 22.74% of total shares; concert party Lü Jianming holds 2,091,088 shares (0.47%) with no pledge. Pledges maturing in the next six months: 21.67 million shares (14.3% of holdings, 4.88% of total shares); pledges maturing in the next year: 57.283221 million shares (37.79% of holdings, 12.89% of total shares). The company states risks are controllable and will not lead to a change in control. Similar pledge announcements were also made on 2026-08-12 and 2026-06-18. Sources: Shanghai Securities News, China Fund News, East Money. Note: Controlling shareholder pledge ratio is approximately 2/3 (combined personal + concert party basis 65.78%), which is at a relatively high level and should be flagged as a governance/liquidity risk.

4.7 2026 Semi-Annual Results

Semi-annual report disclosed on the evening of 2026-08-14: operating revenue RMB 1.586 billion (YoY +4.10%), net profit attributable to parent RMB 458 million (YoY +32.70%), non-GAAP net profit attributable to parent RMB 325 million (YoY +5.74%), basic EPS RMB 1.03. By quarter: Q2 net profit RMB 272 million, Q1 net profit RMB 187 million (implying Q2 QoQ +45%). Key note: Attributable growth of 32.7% vs. non-GAAP growth of 5.74%, a difference of approximately 27 percentage points, indicating that non-recurring gains and losses contributed significantly to current period profit, and the actual core business growth rate is closer to single digits. Results briefing: Announced for convening on 2026-08-24, disclosure of convening status on 2026-08-31 (specific Q&A content not obtained). Whether a "results preview" was issued: As of the search, no separate results preview/pre-increase announcement was seen for the 2026 semi-annual report, with results primarily directly disclosed through periodic reports. Sources: Xinhua Finance, Shanghai Securities News, China Fund News, Gelonghui, Stockstar.

4.8 Uncertainties/Limitations to Note

1. Single-source data: The counterparty's "two enforcement cases totaling RMB 520 million" appears only in media reports such as Economic Information Daily, without company announcement confirmation; cite with caution. 2. Date basis: Multiple sources show dates in 2026 (latest announcement 2026-09-10); please uniformly read as "as of September 2026"; the repurchase transaction price range of RMB 33.53–36.66 is only the company's own purchase price and cannot be equated with the current market price. 3. Items not obtained: Capital flows within September 2026 (net inflow/outflow of main funds), latest closing price and market cap, etc. were not confirmed in this search. 4. Results briefing Q&A content and the specific titles and content of the 2026-07-24/07-31 announcements were not obtained; recommend subsequent verification against original announcements on Cninfo/SSE. 5. Authoritative verification recommendation: All announcements should be based on the original texts on the SSE official website and Shanghai Securities News announcement page; most third-party sources cited herein are announcement reprints with highly consistent content and relatively high credibility, but individual summaries may have abridgements.

4.9 One-Sentence Summary

As of September 2026, Topchoice Medical's recent news flow is dominated by "repurchase completed and cancelled (approximately RMB 99.50 million, 0.63% of shares)," "directors and senior management completed shareholding increase (RMB 7.7578 million)," "controlling shareholder high-frequency pledge/release with cumulative pledge of approximately 66.68%," and "2026H1 net profit attributable to parent +32.7% but non-GAAP only +5.74%," with the biggest controversy and regulatory focus being the RMB 600 million high-premium (Hangzhou Cunji appreciation rate 1,282.14%) related-party acquisition of optometry assets disclosed in March 2026 and approved by shareholders' meeting in April (has received SSE regulatory work letter, media questioning benefit tunneling and counterparty enforcement cases).

5. Stock Price Trend and Technical Analysis

5.1 Price Overview

Indicator	Value
Stock Name/Code	Topchoice Medical (600763.SH, SSE Main Board, margin trading and Shanghai Stock Connect target)
Closing Price	RMB 32.75
Change	-RMB 0.75 / -2.24%
Open / High / Low / Previous Close	RMB 33.30 / 33.44 / 32.56 / 33.50
Volume	67,400 lots (67,370 lots)
Turnover	RMB 221 million
Turnover Rate	1.52%
Amplitude	2.63%
Volume Ratio	0.94
Limit Up / Limit Down Price	RMB 36.85 / 30.15
Total Market Cap / Free Float Market Cap	RMB 14.556 billion / RMB 14.556 billion (fully circulating)
Total Shares / Free Float Shares	444 million / 444 million (some quote pages show 447 million, difference of approximately 0.7%, due to basis/timing differences, sources not unified)
52-Week High / 52-Week Low	RMB 52.22 / RMB 32.53 (consistent across multiple sources)

5.2 Technical Indicators

Indicator	Value	Brief Interpretation
Dynamic P/E	15.88 (stcn, 9fzt, Sina "dynamic P/E")	Significantly lower than TTM basis, because it is calculated by annualizing 2026 semi-annual report net profit attributable to parent of RMB 458.4 million (approximately RMB 917 million); does not represent operating valuation level
P/E (TTM)	22.77 (Cailian Press) / 23.67 (Sina) / 24.56 (MSN earlier date) / 24.96 (Sina 09-09 page)	Multiple source bases dispersed; approximately 23x is closer to the normal operating basis
Static P/E	29.00 (Cailian Press, Sina)	Higher than dynamic and TTM bases, reflecting historical earnings base differences
P/B	3.52–3.61 (Sina 3.52 / stcn 3.61 / Cailian Press 3.54 / 9fzt 3.54)	Slight differences across sources, overall around 3.5x
Net Assets Per Share	RMB 9.2481 (Cailian Press)	Used for P/B basis verification
P/S TTM	4.89 (Sina)	Related to healthcare services industry characteristics
EPS	RMB 1.0314 (2026H1 basic EPS, Sina)	2026 H1 basic earnings per share
2026H1 Operating Revenue	RMB 1.586 billion (+4.10%) (Baidu Finance, East Money)	Single-digit revenue growth
2026H1 Net Profit Attributable to Parent	RMB 458 million (+32.70%) (Baidu Finance, East Money)	High headline growth, but includes non-recurring gains and losses contribution
2026H1 Non-GAAP Net Profit	RMB 325 million (+5.74%) (Baidu Finance, East Money)	Non-GAAP growth vs. attributable growth differ by nearly 27 percentage points, the main reason for the low dynamic PE
Turnover Rate / Volume Ratio	1.52% / 0.94 (2026-09-11, consistent across multiple sources)	Low turnover, volume ratio below 1, relatively light trading
Amplitude	2.63% (2026-09-11)	Intraday fluctuation range relatively narrow

As of the 2026-09-11 close, Topchoice Medical closed at RMB 32.75, down 2.24%, with volume ratio 0.94, turnover rate 1.52%, and turnover of RMB 221 million, indicating relatively light trading. Intraday low was RMB 32.56, only approximately RMB 0.03 from the 52-week low of RMB 32.53, in the 52-week low range (52-week high RMB 52.22, low RMB 32.53), representing a price structure close to the lower edge of the range. Valuation bases require careful differentiation: Dynamic PE 15.88x is calculated by annualizing 2026H1 net profit attributable to parent (458.4×2≈RMB 917 million), while 2026H1 non-GAAP net profit was RMB 325 million, up only +5.74% YoY (net profit attributable to parent +32.70% YoY), with a growth rate difference of nearly 27 percentage points, and non-recurring gains and losses contributed significantly; therefore, the low dynamic PE does not represent the operating valuation level, and TTM of approximately 23x (multi-source 22.77–24.96) is closer to the normal basis. The report does not provide complete moving average, Bollinger Band, MACD/RSI and other technical indicator values, so this section cannot provide corresponding indicator readings based on facts; related technical positions will be described below only on a range basis using available price data (closing price, intraday high/low, 52-week high/low), without fabricating missing values.

5.3 Short-Term Trend Outlook (Next Week, Scenario Analysis, For Reference Only)

⚠️ Risk Warning: The following content is only a short-term technical subjective scenario analysis based on the 2026-09-11 closing data and price information already available in the report. The scenario weights are subjective heuristic judgments based on current technical patterns and capital flows, not statistical probabilities, and do not constitute investment advice. Please make independent judgments in conjunction with the latest market information.

① Key Technical Levels

Level	Range	Description
Short-Term Resistance	RMB 33.4~33.5	Corresponds to the near-term resistance band formed by the 09-11 intraday high of RMB 33.44 and previous close of RMB 33.50; if effectively broken and held, upside space needs to be reassessed in conjunction with subsequent volume and longer-term moving average structure (report does not provide moving average/Bollinger Band values, so no higher-level target can be given)
First Support	RMB 32.5~32.6	Corresponds to the near-term support band formed by the 09-11 intraday low of RMB 32.56 and the 52-week low of RMB 32.53; this range is also the lower edge of the current price range, and whether it holds is relatively critical for short-term structural judgment
Strong Support	Below RMB 32.5 (approximately below RMB 32.5)	The 52-week low of RMB 32.53 is the lowest reference level confirmable within the report; if this level is effectively broken, the report does not provide lower technical reference levels (such as lower band/previous low), and real-time data should be referenced to reassess downside space; specific downside targets should not be given based on this report

② Next-Week Scenarios (Subjective Weights, Not Statistical Probabilities)

Range-bound consolidation (relatively higher weight, approximately 60% (subjective heuristic weight, not statistical probability)): Price repeatedly consolidates within the RMB 32.5~33.5 range, fluctuating between the 52-week low and the near-term resistance band. Trigger conditions: Turnover remains at the current light level of approximately RMB 200 million, volume ratio continues below 1, no clear news catalyst. Given the 09-11 volume ratio of 0.94 and turnover of 1.52%, this scenario best matches current capital flow characteristics.
Weaker downside (moderate weight (subjective heuristic weight, not statistical probability)): If price effectively breaks below the first support near RMB 32.5 (the 52-week low of RMB 32.53 area), downside testing space may open up. Trigger conditions: Turnover significantly increases from recent levels with downward direction, or the healthcare services sector weakens overall, or negative news disturbances emerge. Note: The report does not provide technical reference levels below the 52-week low, and further downside space cannot be quantified based on this report.
Rebound strengthening (lower weight (subjective heuristic weight, not statistical probability)): If price stabilizes near RMB 32.5 and breaks above the RMB 33.4~33.5 resistance band with volume, a phased rebound may occur. Trigger conditions: Single-day turnover significantly increases (volume confirmation signal see below), sector or news provides positive catalyst. This scenario requires volume confirmation; if price rebounds without volume increase, its sustainability lacks sufficient basis.

③ Capital and Liquidity Background

On liquidity, the confirmable data in the report is: 2026-09-11 turnover rate 1.52%, turnover RMB 221 million, volume 67,400 lots, volume ratio 0.94, total market cap and free float market cap both RMB 14.556 billion (fully circulating, total shares and free float shares both approximately 444 million, with some pages showing 447 million, difference of approximately 0.7%). The report does not provide a complete range series of recent turnover, nor data on top ten shareholder concentration, or information on whether institutional holders such as public funds/social security/QFII appear in the top ten shareholder list. The above fields are missing from this report and cannot be filled based on facts; separate retrieval is needed before judgment; if shareholder structure data is subsequently obtained, its data cutoff reporting period (typically lagging by more than one quarter) should be clearly noted, with a warning that the structure may have changed. Based on confirmed data, the turnover rate of 1.52% and volume ratio of 0.94 point to relatively light current trading; given the fully circulating market cap of RMB 14.556 billion, single-day turnover of RMB 221 million means limited order book depth, and large transactions may face relatively wider slippage, a characteristic particularly evident in low-volume conditions.

Volume confirmation signal: Based on near-term turnover within the report, 09-11 turnover RMB 221 million, volume ratio 0.94, 10 days earlier 09-01 turnover RMB 209 million, 09-09 RMB 148 million; if subsequent single-day turnover continues to expand significantly above the RMB 200 million level (for example, consecutively above RMB 300 million with price holding above the RMB 33.4~33.5 resistance band), this can be regarded as a signal of capital involvement; specific thresholds can be dynamically calibrated based on actual turnover ranges in the latest few trading days.

④ Points of Attention (Observation Thoughts Only, Not Trading Instructions)

Monitor whether the RMB 32.5~32.6 range (overlapping band of 09-11 intraday low RMB 32.56 and 52-week low RMB 32.53) holds; this is the lower-edge reference level of the current price structure (observation thought, not trading instruction).
Monitor near-term resistance performance at the RMB 33.4~33.5 range (formed by 09-11 high of RMB 33.44 and previous close of RMB 33.50); upward breakout requires volume confirmation (observation thought, not trading instruction).
Monitor whether single-day turnover can continue to expand significantly above the recent RMB 200 million level, as a verification signal of changes in capital participation (observation thought, not trading instruction).
Monitor valuation basis differences: The gap between dynamic PE 15.88x and TTM approximately 23x stems from 2026H1 non-recurring gains and losses contribution (attributable +32.70% vs. non-GAAP +5.74%); subsequent earnings disclosure may change the valuation reference (observation thought, not trading instruction).

The above scenario analysis is based on 2026-09-11 closing data and historical price, valuation, and capital flow information available in this report, and does not include technical indicators missing from the report (moving averages, Bollinger Bands, MACD, RSI, etc.) or top ten shareholder concentration data; scenario weights are subjective heuristic judgments based on current technical patterns and capital flows, not statistical probabilities, and do not represent the actual future probability distribution. Short-term stock prices are also affected by multiple factors including news, capital flows, and overall market environment; technical indicators themselves have lag and limitations, do not guarantee actual future trends, and do not constitute buy/sell recommendations. Please make independent judgments in conjunction with the latest market information and bear investment risks yourself.

6. Industry Landscape and Competitor Analysis

6.1 Industry Status

China's dental healthcare services market was approximately RMB 119.9 billion in 2020 (RMB 75.7 billion in 2015, 2015–2020 CAGR approximately 9.6%); of which private was approximately RMB 83.1 billion, accounting for 69.3%. Private dental services 2015–2030 CAGR approximately 12.3% (public 8.2%), private share approximately 2/3. Industry concentration is extremely low, highly dependent on doctor resources, and cross-regional expansion management is difficult; in 2022, by market share ranking, Topchoice Medical was only 3.1% (first). Structural variables include volume-based procurement of dental implants reshaping the pricing system, expected extension of orthodontics volume-based procurement, increasing penetration of early childhood orthodontic treatment, digitalization/supply chain integration cost reduction by leading institutions, and downstream M&A.

6.2 Competitive Landscape

Extremely low concentration: The private dental industry is highly fragmented, highly dependent on doctor resources, and cross-regional expansion management is difficult. In 2022, by market share ranking, Topchoice Medical was only 3.1% (first), Arrail Group 1.6% (fourth), Yaboshi 1.2% (fifth) — even the "leader" has only single-digit market share, with large industry consolidation space.
Structural Variable One: Dental implant volume-based procurement (2022 special governance + inter-provincial alliance volume-based procurement from April 2023) reshaped the pricing system; the industry shifted from "high-margin expansion" to "volume offsetting price + efficiency improvement."
Structural Variable Two: Orthodontics driven by appearance economy/domestic cost-effectiveness, with expectations of volume-based procurement extending to orthodontics.
Structural Variable Three: Increasing penetration of early childhood orthodontic treatment; the industry shifting from "passive treatment" to "full lifecycle health management."
Structural Variable Four: Leading institutions increasingly adopting digitalization/3D printing, supply chain integration for cost reduction, downstream penetration and M&A.
Barriers to Entry: Doctor qualifications and clinical experience, equipment investment, brand and compliance regulation → threat from potential entrants is relatively small, but existing competitors are numerous (dental hospitals at all levels, clinics, standalone practices).

6.3 Major Competitors

Company	Positioning	Description
Topchoice Medical (600763.SH)	"Flagship hospital + branch hospitals + Dandelion partners," regional focus on Yangtze River Delta/Zhejiang	Largest network and doctor density in China, extremely low sales expense ratio (approximately 0.9% in 2024), brand "Dental Moutai"; added optometry from 2026H1. 2023 revenue RMB 2.847 billion, 84 institutions, 2,133 doctors; 2025 revenue RMB 2.913 billion, attributable to parent RMB 502 million; 2022 market share 3.1% (first)
Arrail Group (6639.HK)	High-end chain, "Arrail Dental" (high-end) + "Rytime Dental" (second-tier)	First-tier city high-net-worth clientele, doctor reputation for customer acquisition, four-handed dentistry, brand barrier at high end. FY2022 revenue RMB 1.624 billion, approximately 123 institutions, 1,442 dental chairs, 914 full-time doctors; 2022 market share 1.6% (fourth)
Yaboshi (874689, NEEQ, seeking A-share IPO in 2026)	Mid-to-high-end chain, mainly orthodontics + implants	High per-dentist utilization, fast break-even; but abnormally high sales expense ratio of 27.21%, net margin only 8.79%, customer acquisition heavily dependent on Baidu bidding. 2025 revenue RMB 1.767 billion, net profit attributable to parent RMB 137 million, gross margin 51.20%; 2022 market share 1.2% (fifth)
Keen Dental (830938)	Regional chain, mainly within Shandong Province	Regional deepening, fast per-dentist output improvement; detailed data not obtained
Lantian Dental (873101)	100% presence in Guangxi	Single-region concentration; detailed data not obtained

Topchoice is the "regional high-density + low customer acquisition cost" type; Arrail is the "first-tier high-end brand" type; Yaboshi is the "high gross margin + high marketing spend, low net margin" type. Industry-wide net margin is highest for Topchoice (approximately 20% in 2025), Yaboshi only approximately 8.79%, Arrail narrowing losses in recent years. Other peers: Huamei Dental 833269 (Sichuan), Huachi Dental 873311; Hong Kong-listed/unlisted Bybo Dental, Meihui Dental, Meiao Dental and other leading chains are not yet listed. Note that financial data years differ across companies and bases may differ.

7. Risk Warnings

Insufficient core business growth quality: 2026H1 operating revenue grew only 4.10%, non-GAAP net profit attributable to parent grew 5.74%, significantly lower than the headline net profit attributable to parent growth of 32.70%; if the impact of non-recurring gains and losses weakens, profit growth may fall back to single-digit levels closer to the core business.
Dental implant volume-based procurement and price decline risk: The company's implant business accounts for approximately 20% of healthcare service revenue in terms of magnitude, and 2025 implant revenue already declined 2.08% year-over-year; volume-based procurement continues to压低 implant and related service prices; if patient volume growth is insufficient to offset unit price and technical service fee declines, gross margin may continue to be pressured.
Optometry related-party acquisition and integration risk: The company acquired 4 optometry companies controlled by the actual controller for RMB 600 million in cash; core target Hangzhou Cunji book net assets approximately RMB 50.8779 million, appraised value approximately RMB 703 million, appraisal appreciation rate 1,282.14%; the transaction has received an SSE regulatory work letter, and there are subsequent uncertainties regarding valuation fairness, related-party transaction necessity, integration effectiveness, and performance commitment fulfillment.
Optometry performance fulfillment risk: The acquired targets must commit to cumulative profit of no less than RMB 180 million for 2026–2028 and no less than RMB 300 million for 2026–2030, but targets such as Ningbo Guangji and Xinchang Guangji were still at a loss or at very small business scale in 2025; if synergy effects fall short of expectations, returns from the new business may be affected.
Regional concentration and expansion risk: 2026H1 revenue from within Zhejiang Province accounted for 90.50%, out-of-province revenue declined 10% year-over-year; the company is highly dependent on the Zhejiang regional market; if intra-province competition intensifies, consumer demand weakens, or out-of-province institutional expansion continues to be unsuccessful, overall growth space may be limited.
Doctor resources and operational efficiency risk: The company relies on flagship hospital expert resources, regional brand, and the "Dandelion" doctor partnership mechanism; business expansion requires continuous improvement of doctor productivity and maintenance of core doctor stability; if doctor incentives, partner management, or major department system reform effects fall short of expectations, outpatient volume, average ticket size, and branch hospital profitability may be affected.
Controlling shareholder pledge and governance risk: As of September 10, 2026, controlling shareholder Baoqun Industrial's cumulative pledged shares accounted for approximately 66.68% of its holdings and approximately 22.74% of total shares; relatively large-scale pledged shares will mature in the next six months and one year respectively; although the company states risks are controllable, a high pledge ratio may amplify stock price volatility and shareholder liquidity pressure.
Valuation judgment disturbed by non-recurring gains and losses: The company's dynamic P/E of approximately 15.88x is mainly calculated by annualizing 2026 H1 net profit attributable to parent, while TTM P/E is approximately 23x and static P/E is approximately 29x; if one-time gains are mistaken for normal earnings, the actual valuation level may be underestimated.
Short-term trading liquidity risk: As of September 11, 2026, the company's turnover rate was 1.52%, volume ratio 0.94, turnover RMB 221 million, with the stock price near the 52-week low; if it breaks below support near RMB 32.5 with increased volume, the technical picture may further weaken, and the company lacks confirmed lower technical reference levels.

8. Conclusion and Outlook

Topchoice Medical's medium-to-long-term growth foundation still comes from the low concentration of the dental healthcare industry, the high-density network in Zhejiang, the doctor partnership mechanism, and the potential implant volume growth brought by post-volume-based procurement price penetration. If the company can continuously improve doctor productivity, expand general dentistry and restoration businesses, improve patient coverage for orthodontics and implants, and reduce consumable costs through direct manufacturer procurement and group centralized procurement, there is room for gross margin and operating margin recovery. The optometry business may form dental-optometry synergy through "Bright Eyes and White Teeth," but its contribution still needs to be verified through subsequent revenue, profit, and performance commitment fulfillment.

Short-term performance judgment should focus on non-GAAP profit rather than the net profit attributable to parent headline. 2026H1 non-GAAP net profit attributable to parent grew only 5.74%, combined with essentially flat 2025 revenue and net profit attributable to parent, indicating the company is still in a recovery phase from industry policy shocks and implant business price decline impacts. Consensus estimates project 2026–2028 revenue of RMB 3.363 billion, RMB 3.783 billion, and RMB 4.225 billion respectively, and net profit attributable to parent of approximately RMB 601 million, RMB 677 million, and RMB 766 million respectively, but institutional forecast ranges show significant divergence, and subsequent fulfillment depends on core business growth rate, optometry integration, and profitability improvement.

The company's current main contradiction lies in the coexistence of regional leader advantages with business and governance risks: high intra-province concentration and low customer acquisition costs support competitiveness, but out-of-province expansion is weak; the dental core business has good cash flow, but the high valuation of the optometry related-party acquisition, regulatory attention, and the relatively high pledge ratio of the controlling shareholder add uncertainty. The stock price is near the 52-week low with light trading, and the market is still repricing growth quality, asset acquisition fairness, and subsequent profit recovery; going forward, comprehensive observation should be made in conjunction with non-GAAP performance, optometry performance commitments, business regional expansion, and volume changes.

Data Sources

Reports are generated by AI from public online information and may contain errors or outdated information. They are for research only, not investment advice. Verify material facts against company filings and authoritative sources.